Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology reports 36% response rate for MICVO in head and neck cancer trial

Mixed Impact 4 of 5 other Written later

Pyxis Oncology (Nasdaq: PYXS) reported updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma, with a data cutoff of August 18, 2026. The company reported a 36% confirmed objective response rate among 33 efficacy-evaluable patients and said no new safety signals were observed, but 54.3% of the 35 safety-evaluable patients had treatment-related adverse events of grade 3 or higher. The company plans to initiate a pivotal Phase 3 study in mid-2027.

Key points

  • Confirmed objective response rate of 36% (12 of 33) and disease control rate of 94% (31 of 33)
  • Median progression-free survival of 6.2 months; 12-month overall survival probability of 79%; median overall survival not yet reached
  • Grade 3 or higher treatment-related adverse events in 54.3% of patients (19 of 35); 5 patients (14.3%) discontinued treatment due to these events
  • End of Phase 2 meeting with the FDA expected in the first quarter of 2027; Phase 3 Headliner trial planned to start in mid-2027

The filing

CompanyPyxis Oncology, Inc. (PYXS)
Form8-K, current report
Filed with the SECSep 9, 2026, 7:34 AM ET
Accession number0001193125-26-385901

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.